SCHEMBL11999142

SCHEMBL11999142

CC(=O)c1ccc(CC(C(=O)Nc2ccc(-c3cc4ccccc4o3)cc2)c2ccc(C3=CCCCC3)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 7/20 0.59
ADCY6 O43306 6/20 0.59
ADCY3 O60266 6/20 0.59
ADCY9 O60503 6/20 0.59
ADCY5 O95622 6/20 0.59
ADCY8 P40145 6/20 0.59
ADCY7 P51828 6/20 0.59
ADCY2 Q08462 6/20 0.59
ADCY1 Q08828 6/20 0.59
ADCY4 Q8NFM4 6/20 0.59
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
NFKB1 P19838 1/20 0.48
NPY1R P25929 1/20 0.48
NFKB2 Q00653 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2659331 0.93 GCGR (0.60) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2658728 0.92 GCGR (0.58) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2659142 0.89 GCGR (0.54) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2659139 0.89 GCGR (0.54) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL11999141 0.87 ADCY6 (0.64) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2669626 0.86 GCGR (0.63) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL15676223 0.85 GCGR (0.62) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL15676224 0.85 GCGR (0.61) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL11969918 0.85 ADCY6 (0.52) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL11999184 0.84 GCGR (0.63) GCGRADCY6ADCY3ADCY9ADCY5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 US disclosed
US-9701626-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2017-07-11 US disclosed
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2016-01-14 US disclosed
US-9169201-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2015-10-27 US disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.